HIGHLIGHTS
- who: Antibody-drug conjugate from the Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy have published the research work: Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences, in the Journal: (JOURNAL)
- what: The POLAR BEAR trial, focusing on elderly DLBCL patients, is comparing R-mini-CHOP against R-mini-CHP + polatuzumab vedotin in the first line setting (NCT04332822). Multiple myeloma-related targets: BCMA, CD38, CD46, CD56, CD74, CD138 ADCs targeting BCMA, CD38, CD46, CD56, CD74, CD138 are not discussed here since this special issue contains another . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.